301509SZSE
🚨 Material Event

2026 Restricted Stock and Stock Appreciation Rights Incentive Plan (Draft) Summary

Jinkai Biotech Co., Ltd.··31 pages

✨ AI Summary

Jinkai (Liaoning) Life Science Co., Ltd. proposes an incentive plan granting 2.07 million restricted shares and 320,000 stock appreciation rights to 93 eligible employees. The plan aims to align the interests of management and core personnel with company performance. The grant price for both instruments is set at 15.13 yuan per share. The plan is subject to shareholder approval and is designed to support long-term growth and retention.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 301509 Stock Abbreviation: Jinkai Life Science Announcement No.: 2026-019

Jinkai (Liaoning) Life Science Co., Ltd.

2026 Restricted Stock and Stock Appreciation Rights Incentive Plan (Draft) Summary

July 2026

Statement

The Board of Directors and all directors of the Company guarantee that the contents of this announcement do not contain any false records, misleading statements, or major omissions, and assume legal responsibility for the authenticity, accuracy, and completeness of its contents.

All incentive recipients of the Company undertake that if the Company is found to have false records, misleading statements, or major omissions in its information disclosure documents, resulting in non-compliance with the conditions for granting or vesting/exercising rights, the incentive recipients shall return all benefits obtained from this incentive plan to the Company after the relevant information disclosure documents are confirmed to contain such false records, misleading statements, or major omissions.

Special Notice

  1. This incentive plan is formulated in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Administrative Measures on Equity Incentives of Listed Companies, the Shenzhen Stock Exchange GEM Stock Listing Rules, the Shenzhen Stock Exchange GEM Listed Company Self-Regulatory Guidelines No. 1 — Business Handling, and other relevant laws, regulations, and normative documents, as well as the Articles of Association of Jinkai (Liaoning) Life Science Co., Ltd.

  2. This incentive plan includes two independent parts: the Restricted Stock Incentive Plan (Type II Restricted Stock) and the Stock Appreciation Rights Incentive Plan. The source of the restricted stock is the Company's定向 issuance of A-share common stock to the incentive recipients. After meeting the corresponding vesting conditions, the incentive recipients will obtain the Company's A-share common stock issued to them at the grant price, which will be registered with the Shenzhen Branch of China Securities Depository and Clearing Corporation. Before vesting, the restricted stock granted to the incentive recipients does not carry shareholder rights and may not be transferred, used for guarantees, or used to repay debts. Stock appreciation rights do not involve actual shares of the Company; they use the Company's A-share common stock as the virtual underlying stock, with one stock appreciation right virtually corresponding to one A-share common stock. Subject to performance assessment standards, the Company will pay the incentive amount in cash.

  3. This incentive plan intends to grant 2.07 million restricted shares to incentive recipients, accounting for approximately 1.72% of the Company's total share capital of 120.446669 million shares at the time of the announcement of this draft. The grant of restricted stock under this plan is a one-time grant with no reserved interests. At the same time, it is intended to grant 320,000 stock appreciation rights to incentive recipients, accounting for approximately 0.27% of the Company's total share capital of 120.446669 million shares at the time of the announcement of this draft. Of this, 270,000 shares are granted for the first time, accounting for approximately 0.22% of the total share capital, representing 84.38% of the total equity granted this time; 50,000 shares are reserved, accounting for 0.04% of the total share capital, representing 15.63% of the total equity granted this time.

The total number of underlying shares involved in all of the Company's equity incentive plans within the validity period does not exceed 20.00% of the Company's total share capital at the time of the announcement of this draft. The cumulative number of the Company's shares granted to any single incentive recipient through all equity incentive plans within the validity period does not exceed 1.00% of the Company's total share capital at the time of the announcement of this draft.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.